Premium
Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression
Author(s) -
Yaribeygi Habib,
SimentalMendía Luis E.,
Barreto George E.,
Sahebkar Amirhossein
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.28420
Subject(s) - adipokine , adipose tissue , adiponectin , adipocyte , glucose homeostasis , endocrinology , medicine , energy homeostasis , insulin , leptin , carbohydrate metabolism , insulin resistance , biology , obesity
Several classes of antidiabetic agents have been developed that achieve their hypoglycemic outcomes via various molecular mechanisms. Adipose tissue is a major metabolic and energy‐storing tissue and plays an important role in many metabolic pathways, including insulin signaling and insulin sensitivity. Adipose tissue monitors and regulates whole body homeostasis via production and release of potent proteins, such as adipokine and adiponectin, into the circulation. Therefore, any agent that can modulate adipocyte metabolism can, in turn, affect metabolic and glucose homeostatic pathways. Antidiabetic drugs are not only recognized primarily as hypoglycemic agents but may also alter adipose tissue itself, as well as adipocyte‐derived adipokine expression and secretion. In the current review, we present the major evidence concerning routinely used antidiabetic agents on adipocyte metabolism and adipokine expression.